Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint

CD40 免疫系统 生物 免疫学 B细胞受体 细胞生物学 癌症研究 B细胞 抗体 细胞毒性T细胞 生物化学 体外
作者
Tingting Tang,Xiang Chao Cheng,Billy Truong,Lizhe Sun,Xiaofeng Yang,Hong Wang
出处
期刊:Pharmacology & Therapeutics [Elsevier BV]
卷期号:219: 107709-107709 被引量:297
标识
DOI:10.1016/j.pharmthera.2020.107709
摘要

The CD40 receptor and its ligand CD40L is one of the most critical molecular pairs of the stimulatory immune checkpoints. Both CD40 and CD40L have a membrane form and a soluble form generated by proteolytic cleavage or alternative splicing. CD40 and CD40L are widely expressed in various types of cells, among which B cells and myeloid cells constitutively express high levels of CD40, and T cells and platelets express high levels of CD40L upon activation. CD40L self-assembles into functional trimers which induce CD40 trimerization and downstream signaling. The canonical CD40/CD40L signaling is mediated by recruitment of TRAFs and NF-κB activation, which is supplemented by signal pathways such as PI3K/AKT, MAPKs and JAK3/STATs. CD40/CD40L immune checkpoint leads to activation of both innate and adaptive immune cells via two-way signaling. CD40/CD40L interaction also participates in regulating thrombosis, tissue inflammation, hematopoiesis and tumor cell fate. Because of its essential role in immune activation, CD40/CD40L interaction has been regarded as an attractive immunotherapy target. In recent years, significant advance has been made in CD40/CD40L-targeted therapy. Various types of agents, including agonistic/antagonistic monoclonal antibodies, cellular vaccines, adenoviral vectors and protein antagonist, have been developed and evaluated in early-stage clinical trials for treating malignancies, autoimmune diseases and allograft rejection. In general, these agents have demonstrated favorable safety and some of them show promising clinical efficacy. The mechanisms of benefits include immune cell activation and tumor cell lysis/apoptosis in malignancies, or immune cell inactivation in autoimmune diseases and allograft rejection. This review provides a comprehensive overview of the structure, processing, cellular expression pattern, signaling and effector function of CD40/CD40L checkpoint molecules. In addition, we summarize the progress, targeted diseases and outcomes of current ongoing and completed clinical trials of CD40/CD40L-targeted therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
jy完成签到,获得积分10
2秒前
shelter完成签到,获得积分10
2秒前
多情天荷完成签到,获得积分10
2秒前
开放灭绝完成签到,获得积分10
3秒前
3秒前
无极微光的应助被梅花采纳,获得20
3秒前
4秒前
思源的应助被xueee采纳,获得10
4秒前
所所的应助被Adamcssy19采纳,获得100
4秒前
maoning完成签到,获得积分10
4秒前
5秒前
yerong发布了新的文献求助10
5秒前
万能图书馆的应助被zhuzihao采纳,获得10
6秒前
不停发布了新的文献求助10
7秒前
7秒前
7秒前
Ting发布了新的文献求助10
7秒前
7秒前
花花完成签到,获得积分10
7秒前
小奇完成签到,获得积分10
8秒前
田様的应助被Jsl采纳,获得10
8秒前
裴依菲完成签到,获得积分10
8秒前
黎明发布了新的文献求助10
9秒前
9秒前
传奇3的应助被小安采纳,获得10
10秒前
妮子发布了新的文献求助10
10秒前
11秒前
云馨完成签到,获得积分0
11秒前
欢呼的过客完成签到,获得积分10
11秒前
自由的诗兰完成签到,获得积分10
11秒前
12秒前
科目三的应助被penguin采纳,获得10
12秒前
不停完成签到,获得积分10
12秒前
GGG完成签到,获得积分20
12秒前
13秒前
余香的应助被TNBD采纳,获得10
14秒前
14秒前
Chamomile发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153573
求助须知:如何正确求助?哪些是违规求助? 9550279
关于积分的说明 21697424
捐赠科研通 7742161
什么是DOI,文献DOI怎么找? 3425546
关于科研通互助平台的介绍 2550636
邀请新用户注册赠送积分活动 2469181